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 
Abstract—Neuroprostheses aimed to restore lost functions 
after a limb amputation are based on the interaction with the 
nervous system by means of neural interfaces. Among the 
different designs, intraneural electrodes implanted in peripheral 
nerves represent a good strategy to stimulate nerve fibers to send 
sensory feedback and to record nerve signals to control the 
prosthetic limb. However, intraneural electrodes, as any device 
implanted in the body, induce a foreign body reaction (FBR) that 
results in the tissue encapsulation of the device. The FBR causes a 
progressive decline of the electrode functionality over time due to 
the physical separation between the electrode active sites and the 
axons to interface. Modulation of the inflammatory response has 
arisen as a good strategy to reduce the FBR and maintain 
electrode functionality. In this study transversal intraneural 
multi-channel electrodes (TIMEs) were implanted in the rat 
sciatic nerve and tested for 3 months to evaluate stimulation and 
recording capabilities under chronic administration of 
dexamethasone. Dexamethasone treatment significantly reduced 
the threshold for evoking muscle responses during the follow-up 
compared to saline-treated animals, without affecting the 
selectivity of stimulation. However, dexamethasone treatment did 
not improve the signal-to-noise ratio of the recorded neural 
signals. Dexamethasone treatment allowed to maintain more 
working active sites along time than saline treatment. Thus, 
systemic administration of dexamethasone appears as a useful 
treatment in chronically implanted animals with neural 
electrodes as it increases the number of functioning contacts of 
the implanted TIME and reduces the intensity needed to 
stimulate the nerve.  
 
Index Terms— dexamethasone, foreign body reaction, 
intraneural electrode, neuroprosthesis, stimulation. 
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I. INTRODUCTION 
he interface of neuroprosthetic systems intended to 
substitute an amputated limb is based in the stimulation of 
sensory axons to evoke sensory feedback and in the recording 
of motor nerve signals to control the prosthetic device. 
Peripheral nerve electrodes are a key component of 
neuroprostheses, as they are the active part that will interact 
with the nervous tissue [1]. Despite the different designs, most 
nerve electrodes consist of a polymer substrate where metal 
active sites are embedded to deliver current to stimulate nerve 
fibers or to record nerve signals. Therefore, the relative 
position and distance to the nerve fibers will determine the 
intensity needed to stimulate the axons and the quality of the 
recorded signals. Among the different designs developed, 
intraneural electrodes, such as the transversal intrafascicular 
multichannel electrode (TIME), have shown good capabilities 
for selective stimulation and recording in comparison to 
extraneural electrodes [2].  
However, studies in human subjects and animal 
experiments have shown a progressive decline in the 
intraneural electrode functionality over time [3]–[5]. This has 
been attributed, at least in part, to the foreign body reaction 
(FBR) triggered after the implantation of the device [6], [7]. 
The FBR against an intraneural electrode is characterized by 
an initial inflammatory phase, in which polymorphonuclear 
cells and monocytes/macrophages infiltrate the tissue from 1 
day after the implant. This first phase induces a later anti-
inflammatory and tissue-remodeling phase from 8 weeks post-
implant, mainly orchestrated by fibroblasts [8]–[11]. This FBR 
results in tissue encapsulation of the electrodes, leading to a 
physical separation of the active sites from the nerve fibers 
[9], [11] and an increase in the impedance [10], [12]. Since the 
relative position and distance to the nerve fibers is critical to 
determine the intensity needed to stimulate the axons and the 
quality of the recorded signals, the capsule tissue around the 
electrode clearly hampers its functionality over time.  
Different strategies have been pursued to improve the long-
term functional outcome of implanted neural electrodes, 
including the use of different polymers as a substrate of the 
electrode [13]–[16], diverse surface coatings [17]–[19] and 
pharmacological modulators of the FBR [20], [21]. One of the 
most used drugs to modulate the FBR is dexamethasone, a 
Long-Term Functionality of Transversal 
Intraneural Electrodes Is Improved By 
Dexamethasone Treatment 
N. de la Oliva1, J. del Valle1,2, I. Delgado-Martínez1, M. Mueller3, Student Member IEEE, T. 
Stieglitz3,4,5, Senior Member IEEE, Xavier Navarro1* 
T 
1534-4320 (c) 2018 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information.
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication. Citation information: DOI 10.1109/TNSRE.2019.2897256, IEEE
Transactions on Neural Systems and Rehabilitation Engineering
TNSRE-2018-00397 2 
glucocorticoid known for its anti-inflammatory and immune-
depressant effects [22]. Dexamethasone administration has 
shown good results in reducing the inflammatory reaction to 
implanted electrodes in the central nervous system [23], [24] 
as well as improving brain recordings [25]. Some studies have 
applied these strategies to peripheral nerve electrodes, as for 
example, using dexamethasone-releasing cuff [26] or 
dexamethasone-loaded multichannel [27] electrodes. 
However, these studies did not take into account the time-
window in which such modulators may be effective or if 
modulation of the FBR has, indeed, positive effects on the 
functional performance of the electrodes for stimulation and 
recording. Systemic administration of drugs for reducing the 
FBR may allow for a better control of dosage and timing 
without modifications in the design of current nerve electrodes 
[28]. Thus, this study aims to evaluate if dexamethasone 
treatment improves the long-term functional outcome of TIME 
electrodes implanted in the rat sciatic nerve.   
II. MATERIAL AND METHODS 
A. Surgical Procedures and Drug Administration 
All animal experiments conducted in this study were 
performed according to protocols approved by the Ethical 
Committee of the Universitat Autònoma de Barcelona in 
accordance with the European Communities Council Directive 
2010/63/EU.  
The electrode used was a transversal intrafascicular 
multichannel electrode (TIME version 3H; developed by the 
Department of Microsystems Engineering-IMTEK, University 
of Freiburg, Germany) [29], [30]. It contains seven active sites 
made of iridium oxide at each arm of the device, with a 
diameter of 80 µm in one arm and a diameter ranging from 20 
to 60 µm in the other. In this study, only the active sites of 80 
µm at one arm were evaluated. The TIME electrodes were 
implanted in the sciatic nerve of female Sprague-Dawley rats 
(n=12, 220±20g). Animals were anesthetized with ketamine 
and xylazine (90/10 mg/kg, i.p.) and the sciatic nerve was 
surgically exposed at the midthigh and freed from adherences 
to surrounding tissues. Following the same procedure as in 
[29], the TIME was transversally inserted across the sciatic 
nerve with the help of a straight needle attached to a 10-0 loop 
thread. All the process was monitored under a dissection 
microscope to ensure the correct position of the active site 
inside the nerve fascicles (Fig. 1A). Since the TIME used was 
originally designed for human nerves, in most cases, only 2-3 
of seven contacts were positioned within the rat sciatic nerve 
at the same time due to dimension mismatch. Then, the 
electrode tip was fixed to the closest muscle with a 10-0 suture 
to avoid the electrode sliding from the nerve and reduce 
motion. The fixation flaps in the arm of the TIME3H were not 
used to fix it to the epineurium, as done in human nerve 
implants [3], to avoid nerve damage. This fixation was chosen 
in order to assess functional stability over time, i.e. to maintain 
the electrode inside the nerve, but without further damaging it. 
The ceramic interconnector, on which the TIME tracks are 
connected to wires, was fixed subcutaneously over the gluteus 
muscles to reduce tethering forces on the electrode. The wires 
were routed inside a thin silicon tube subcutaneously and 
soldered to a Circular Omnetics connector (Nano series) that 
was fixed with a custom-made plastic base on the back of the 
animal to facilitate the connection during the 
electrophysiological tests and covered with a metal protection 
cap (Fig. 1B). The muscles and the skin were closed with 
sutures and the wounds disinfected with povidone-iodine. 
After the surgical procedure, animals were left to recover in 
warm pads. During the follow-up, they were housed at 22±2ºC 
under a 12:12 h light cycle with food and water access ad 
libitum.   
 
Figure 1. Surgical implant of a TIME in the rat sciatic nerve. (A) Photograph 
of the TIME inserted across tibial and peroneal fascicles of the sciatic nerve. 
The tip of the TIME was sutured to the close muscle to avoid motion. Active 
site 1 (square) is almost out but still within the nerve. Scale bar = 1cm. (B) 
View of the back of the animal with the subcutaneous wires and the plastic 
base made to house the Omnetics connector. A metal cup was used to prevent 
damage to the connector. 
Half of the rats were administered daily with 
dexamethasone (n=6, 200 µg//kg subcutaneous; Merck) from 
two days before the surgery to ensure systemic levels and 
during all the follow-up. The other half received injections of 
the same volume of saline vehicle. After 12 weeks post-
implant, animals were deeply anesthetized with an overdose of 
pentobarbital, transcardially perfused with 4% 
paraformaldehyde in phosphate buffer and the sciatic nerve 
including the implanted device harvested for histological 
analysis.  
B. Histological Studies  
The nerve segment including the intraneural electrode was 
embedded in paraffin, and transverse sections (10 µm thick) 
were cut, mounted on silane-coated slides and dried overnight. 
To identify the location of TIME electrode inside the nerve 
and to evaluate the presence of foreign body giant cells 
(FBGCS) and the encapsulating tissue, sections were 
deparaffinized and stained, first overnight with standard luxol 
fast blue (LFB) for myelin visualization, and then with 
hematoxylin Harris solution (Fluka, Sigma) for 7 min, washed 
with water and stained with Eosin Y (Merck Millipore) for 3 
min. Sections were dehydrated with series of graded ethanol 
rinses and mounted with DPX (Sigma). For encapsulation 
measurement, the area and the surface occupied by the 
encapsulating tissue around the electrode were measured, and 
a mean thickness of the capsule was obtained. The number of 
foreign body giant cells (FBGCs) was counted in each section 
(4 sections/animal, n=6/group). 
1534-4320 (c) 2018 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information.
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication. Citation information: DOI 10.1109/TNSRE.2019.2897256, IEEE
Transactions on Neural Systems and Rehabilitation Engineering
TNSRE-2018-00397 3 
C. Nerve Stimulation Protocol  
To assess the stimulation performance of the implanted 
TIMEs, biphasic rectangular current pulses with a width of 
100 µs and an intensity up to 1 mA were delivered (Stimulator 
DS4, Digitimer) through each one of the  active sites against a 
small needle electrode placed near the nerve. The compound 
muscle action potentials (CMAP) were recorded from 
gastrocnemius medialis (GM), tibialis anterior (TA) and 
plantar interossei (PL) muscles using small needle electrodes 
placed in each muscle [2]. The CMAPs were amplified 
(P511AC amplifiers, Grass), band-pass filtered (3 Hz to 3 
kHz) and digitized with a Powerlab recording system 
(PowerLab16SP, ADInstruments) at 20 kHz. The amplitude of 
each CMAP (M wave) was measured peak to peak and 
normalized to the maximum CMAP amplitude obtained in 
each experiment by stimulation of the sciatic nerve with a 
stainless-steel needle electrode. For each active site, the 
threshold current of stimulation that elicited a 5 and 95% of 
the maximum CMAP was determined. The active site with the 
lowest threshold value in each electrode (best AS) was used 
for data analysis and comparison between groups 
(1AS/animal, n=6 at day 0, 7 and 14 and n=5 at day 30 for 
Dex group and n=6 at day 0 and n=4 at day 7, 14 and 30 for 
Saline group). To measure the electrode displacement over 
time, the best active site from each TIME at each time point 
was determined, the difference with respect to the previous 
position calculated and the result multiplied by the distance 
between active sites (400μm). Finally, the selectivity index 
(SI) was calculated to quantify the specific activation of a 
single muscle among the set of three muscles (GM, TA, PL) 
when stimulating from each active site, as previously 
described [2], [31] and the maximum SI (SImax) from each 
TIME for each muscle was used.   
D. Nerve Signals Recording Protocol 
To assess the recording capabilities of TIME electrodes 
over time, two different protocols were performed as 
previously described [32]. First, the compound nerve action 
potentials (CNAPs) were recorded from the TIME following 
electrical stimulation of the distal tibial nerve. Rectangular 
pulses of 100 µs and up to 5 mA (DS4, Digitimer) were 
delivered using two small needles inserted on the medial side 
of the paw. Recordings were made from each active site of the 
TIME against the counter electrode in the ribbon part of the 
TIME (outside the nerve), with a small needle electrode 
subcutaneously inserted as ground. The CNAP amplitude 
recorded from each site was measured peak to peak. The 
maximum amplitude recorded from each TIME was analyzed 
for comparison between groups (N per groups as detailed in 
the nerve stimulation part).  Second, neural activity evoked by 
scratching with a blunt plastic probe the plantar surface of the 
paw (10 repetitions) was recorded from each active site [33]. 
Signals were amplified x5000, band-pass filtered (between 
300 Hz and 10 kHz) and fed to a power-line noise eliminator 
(Hum Bug, Quest Scientific), then digitized at 20 kHz and 
recorded with Chart software (PowerLab System, 
ADInstruments). The total power of the recorded signals and 
the noise (no stimulus applied) was obtained after applying the 
short-time Fourier transform with a window of 1 ms, and an 
overlap of 87.5%. Only the best recording active site in each 
TIME was used to calculate the signal-to-noise ratio (SNR), as 
the ratio between the mean of the total power when the stimuli 
are applied and the mean of the total power when there are no 
stimuli applied.  
Animal body temperature was maintained constant using a 
thermostatic heating pad during the electrophysiological tests. 
Both stimulation and recording protocols were performed 
acutely (0 days, 30 minutes after the implantation) and at 7, 
14, 30, 60 and 90 days after implant or until failure of the 
electrode.  
E. Statistical Analysis 
Results are expressed as the average ± SEM. Normality of 
distribution was tested by the Shapiro-Wilk test. Differences 
between groups or times in normally distributed data were 
analyzed by two-way ANOVA followed by Sidak`s post hoc 
tests. For non-normal variables the analysis was performed 
with the Kruskal–Wallis test followed by Dunn’s test. 
Statistical significance was considered at p < 0.05. The 
GraphPad Prism software was used for all statistical analyses. 
III. RESULTS 
Animals implanted with TIME electrodes and administered 
with dexamethasone or saline were followed for 3 months to 
evaluate electrode functionality. Unfortunately, the wiring 
system got damaged before the final date in some cases. 
Therefore, the comparison between the two groups with 
respect to the electrophysiological results was made up to 1 
month of implantation only (subchronic time-point, [34]), 
whereas histology was performed in all animals at 3 months 
(chronic time-point). 
A. Nerve Stimulation Results over Time 
The current needed to achieve 5% of the maximal CMAP 
(5% threshold) for each active site in each TIME implanted 
showed variations over time depending on the active site (Fig. 
2A). For contacts located inside the nerve immediately after 
implantation, the 5% threshold averaged 70 ± 10 µA in the 
saline-treated group and 60 ± 9 µA in the dexamethasone-
treated group (n=6 per group), whereas half of the active sites 
were outside the nerve and had 5% threshold above 200 µA. 
Interestingly, the active site with the lowest threshold changed 
during the follow-up in each case, indicating a relative motion 
from the original position (at day 0) of the implanted 
electrodes (Fig. 2A-B) and suggesting a dynamic integration 
of the electrode within the nerve rather than a fixed implant, 
that could damage the tissue with its rigidity. Thus, we 
quantified the displacement of the electrodes with respect to 
its original position for the two groups. Saline-treated animals 
presented longer displacement of the electrode than the 
dexamethasone-treated group (1400 ± 200 μm vs 720 ± 366 
μm) during the first week of follow-up, equating to the shift of 
2 or 3 active sites Differences, however, did not reach 
statistical significance (p>0.05, Kruskal-Wallis test). In fact, 
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the position of the electrodes in animals treated with 
dexamethasone was more stable over time (400 ± 179 μm and 
160 ± 98 μm after 14 and 30 days, respectively) than the 
electrodes in the saline-treated group (300 ± 191 μm and 500 
± 252 μm after 14 and 30 days, respectively) with respect to 
the previous position (Fig. 2B).  
 
Figure 2. Changes in stimulation threshold and active sites position within 
the sciatic nerve over time. (A) Schematic view of a given TIME implanted in 
the fascicles of the sciatic nerve and its shift over time, as derived from values 
found in the stimulation protocol. Changes in the active site (AS) position 
correspond to changes in stimulation threshold. (B) Quantification of the 
displacement of implanted TIMEs in saline- and dexamethasone-treated 
groups over time. Each column corresponds to the mean change with respect 
to the previous tested time. 
 
Because of the relative displacement, we used the best 
active site (i.e., the one with the lowest threshold value which 
indicates the best position inside the nerve) for each muscle in 
each electrode for comparison between dexamethasone and 
saline-treated groups. All animals showed a clear increase in 
the threshold current needed for muscle activation, at 5% and 
95% of maximal CMAP, during the first week of follow-up, 
with later stabilization at 14 and 30 days after implant 
(p<0.05). However, rats receiving dexamethasone had 
significantly lower values for GM and TA muscles in 
comparison with the saline-treated group (p<0.05) (Fig. 3), 
indicating that the treatment limited the initial increase in 
tissue resistance. The treated group still maintained lower 
values after 1 month of implant (Fig.3).  
 
Figure 3. Values of stimulation current needed to elicit (A) 5%, (B) 50% and 
(C) 95% of the maximum CMAP amplitude of gastrocnemius (GM),  tibialis 
anterior (TA) and plantar interossei (PL) muscles in saline and dexamethasone 
treated groups over time. Two-way ANOVA, *p<0.05 vs saline-treated group, 
#p<0.05 vs time.  
Additionally, the number of functioning active sites able to 
evoke CMAPs in the muscles recorded decreased over time 
for both groups. However, there were more functioning sites 
during all the follow-up in the dexamethasone-treated than in 
the control group, although the difference was not significant 
(p>0.05, Kruskal-Wallis test, Fig. 4).  
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Figure 4. Number of working active sites (AS) in the TIME that were able to 
evoke a (A) 5%, (B) 50% and (C) 95% of the maximum CMAP amplitude of 
gastrocnemius (GM), tibialis anterior (TA) and plantar interosseus (PL) 
muscles in saline and dexamethasone treated groups at different time points.. 
 
The selectivity of stimulation for the three different muscles 
tested innervated by the sciatic nerve ranged between 0.56 and 
0.9. The SImax was maintained during the follow-up for GM 
(Fig. 5A) and TA (Fig. 5B) muscles, whereas it decreased 
from 0 to 30 days after the implant for the PL muscle, without 
differences between both groups (Fig. 5C).  
 
Figure 5. Maximal selectivity index (SImax) for gastrocnemius (GM), tibialis 
anterior (TA) and plantar interossei (PL) muscles over time in saline and 
dexamethasone treated groups. Two-way ANOVA, #p<0.05 vs time. 
 
B. Nerve signal recording results  
The maximum amplitude of the CNAP, elicited by electrical 
stimulation of the distal tibial nerve and recorded from active 
sites in the TIME, decreased over time in both groups (Fig. 
6A).  Dexamethasone treatment allowed recording CNAPs of 
slightly higher amplitudes, yet not significantly than in control 
rats during the first two weeks of follow-up (Fig. 6A). 
Electroneurographic recordings were performed during 
mechanical stimulation of the hind paw skin. The SNR 
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markedly decreased from 0 to 7 days after the implant and 
remained unchanged during the follow-up (Fig. 6 B, C), 
without differences between both groups at any time point. 
However, dexamethasone treatment resulted in higher number 
of active sites from which afferent nerve signals could be 
recorded during follow-up, yet not significantly (p>0.05, 
Kruskal-Wallis test, Fig.6D). 
 
Figure 6. Recording of nerve signals with TIME.  (A) Representative CNAP 
recordings after 0 and 7 days of implantation (dpi). (B) Maximum CNAP 
amplitude recorded from active sites in TIMEs implanted in the sciatic nerve 
of saline and dexamethasone treated rats. (C) Representative neural activity 
recordings after mechanical stimuli in the paw at 0 and 7 days of implantation. 
(D) Signal-to-noise (SNR) ratio over time in recordings made with TIMEs 
implanted in saline or dexamethasone treated rats. (E) Number of active sites 
(AS) from which recording of nerve signals was obtained with a SNR above 
1.01 over time. Two-way ANOVA, #p<0.05 vs time. 
C. Nerve histology 
The histological evaluation of TIMEs implanted after 3 
months showed that the TIMEs were within the sciatic nerve, 
traversing peroneal and tibial fascicles (Fig. 7A, B). Although 
axons were still close to the active sites, the electrodes were 
surrounded by a thick capsule of fibrotic tissue, as shown by 
the hematoxylin-eosin staining in samples taken after 3 
months of implantation. The capsule thickness was slightly 
lower in dexamethasone-treated rats (54 ± 18 μm) than in the 
saline rats (74 ± 13 μm) (Fig. 7C). Finally, foreign body giant 
cells (FBGCs) were present in close contact with the 
polyimide substrate, but without significant differences in 
number between groups (Fig. 7D).  
 
 
Figure 7. Histological transverse nerve sections stained with LFB-HE showing 
TIMEs implanted in the sciatic nerve of rats after 12 weeks with (A) saline or 
(B) dexamethasone treatment. Dotted lines delimit nerve fascicles: TN = tibial 
nerve, PN = peroneal nerve. Arrow in A points to active sites in the implanted 
electrode. Scale bars in (A-B) 150µm. (C) Quantification of the thickness of 
the capsule formed around the electrode in saline and dexamethasone treated 
groups. (D) Number of FBGCs around the surface of the implanted electrodes 
in each studied group. T-test vs saline-treated group. 
 
IV. DISCUSSION 
Neural electrodes are a key component of interfaces for the 
communication between the nervous system and bionic 
prostheses. Despite the considerable advances achieved in 
biomaterial and electrode designs [1], [35], improved stability 
is desired to maintain the functionality of implanted electrodes 
over long periods of time. One of the factors that contribute to 
the failure or decline of function of neural implants is the FBR 
[9]. The encapsulation of the implanted devices enlarges the 
distance between the axons membrane and the active sites and 
also increases the tissue resistance [36], resulting in an 
increase in the current needed to stimulate the axons and also a 
decrease of the SNR during recordings. This study combines 
two of the most promising strategies to improve the long-term 
functionality of neural implants in peripheral nerves: 
transversal and flexible intraneural electrodes (i.e., TIME) and 
anti-inflammatory treatment (i.e., dexamethasone) by systemic 
administration.  
TIME electrodes have been previously shown to provide 
good stimulation capabilities in animal models [2], [32] and 
humans [3], [4]. Although these studies reported adequate 
values of impedance and injected charge for useful stimulation 
in human patients, an increase in the stimulation threshold was 
observed during the first month of implant. The present study 
is in agreement since the stimulation current needed to activate 
the nerve increased during the first weeks of implant, followed 
by stabilization of the threshold values. Moreover, the 
selectivity indices found in this work are similar to those 
shown in previous studies with intraneural electrodes [2], [10], 
[37], confirming the stable selectivity in subchronic implants. 
However, few works have focused on the recording 
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capabilities of this type of electrode and only in acute 
conditions [32]. Our results on subchronically implanted 
TIME electrodes show a decrease in the amplitude of the 
recorded signals, either compound or single action potentials 
from one week post-implant, although it was stabilized in the 
following weeks.  
Several studies have investigated the effect of anti-
inflammatory drugs on the FBR to neural implants, with 
positive effects on electrode functionality and on the amount 
of FBR [23]–[26]. However, this is the first work in which it 
has been evaluated with intraneural electrodes in the 
peripheral nerve. Dexamethasone administration substantially 
decreased the stimulation intensity needed to activate the 
nerve during the first month of implant. We have previously 
described the time course of the FBR to nerve implants, and 
found that the first phase of the FBR peaks at one month [9], 
and that dexamethasone treatment decreases the amount of 
infiltrating macrophages within the nerve and also the 
thickness of the capsule formed around intraneural devices 
[28]. In this study, we observed that dexamethasone-treated 
animals also had a tendency, yet not significant, to present 
thinner tissue capsule. These changes can be related to the 
decrease in macrophage infiltration in the nerve tissue, as 
demonstrated by lower presence of FBGCs after 3 months of 
implant. Dexamethasone treatment also resulted in better 
functionality of the implanted TIMEs. In particular, there was 
less displacement of the electrode within the nerve during the 
first weeks of implant, confirmed by the maintenance of the 
active sites stimulation profile in the follow-up testing. This 
fact may be in disagreement with the reduction of the tissue 
capsule, since fewer adherences would be expected to be 
related with greater displacement. However, the anti-
inflammatory treatment may decrease not only the cell 
infiltration in the nerve tissue but also the edema after the 
implantation. This edema and the subsequent changes due to 
cell infiltration in the saline-treated group may result in 
weaker adherences and larger electrode motion. Thus, the 
reduction of the stimulation intensity may be due to the 
decrease in capsule thickness around TIME implanted in 
nerves under dexamethasone treatment. In addition to the 
reduced distance between the active sites and the axons to 
stimulate, changes in tissue deposition and cellular infiltration 
may imply changes in the electrical properties of the 
surrounding tissue. In fact, we found more functioning 
contacts able to evoke a muscle response in the treated group. 
Besides, less motion of the electrode within the nerve would 
imply more steady stimulation and recording in subchronic 
implants. This is of particular interest since improved 
bidirectional control of upper limb prostheses is based on 
stimulating specific motor axons and on decoding nerve 
signals using featured-detection algorithms [3], [32], [38]. 
Thus, stable electrodes within the peripheral nerves offer more 
steady signals in subchronic implants. It is worth noting that 
the impact of electrode motion and of tethering forces are 
much larger in rats compared to humans due to the electrode-
nerve size relationship, adding challenges for the resistance of 
electrodes, wires and connectors, which are often among the 
reasons for the loss of functional contacts over time of 
implantation, as previously reported [10]. Indeed, we 
minimized the fixation of the TIME to the rat nerve, compared 
to the surgical procedure used in human implants [3] or the 
implant of SELINE electrodes in rats [10] that secure a stable 
position, in order to assess the effect of intraneural motion.  
A limitation of the present study is the lack of evaluation of 
the electrode itself with e.g. impedance analysis. It is true that 
neural interfaces can loss its functional capabilities not only 
due to biological causes but material degradation or active 
sites corrosion. Further experiments should consider the 
analysis of these parameters. Nevertheless, the reduction of 
FBR with dexamethasone treatment yielded better results with 
the electrodes over time.  
On the other hand, dexamethasone treatment did not 
improve the capability for recording neural signals. The 
quality of the recorded signal relies on the amplitude of that 
signal and the placement of the active site with respect to the 
activated axons. Since the amplitude of nerve signals is on the 
scale of microvolts, the distance between the axons and the 
active site and the capsule tissue characteristics become 
critical to have a good SNR. While the FBR adds about 30 µm 
of separation between the active sites and the axons in 
longitudinal implants [9], in transversal implants the FBR adds 
about 60 µm of tissue capsule, which would explain the rapid 
decay in electrode recording capability. In addition, the 
fibrotic capsule formed around the electrode will presumably 
offer a higher resistivity, that might be comparable to that of 
the perineurium [39]. Even though, probably due to the 
decrease in capsule thickness produced by dexamethasone 
treatment (75 µm vs 55 µm), there were more active sites able 
of recording small nerve signals.  
V. CONCLUSION 
Overall, our results show a positive effect of dexamethasone 
treatment on the capability of intraneural electrodes to 
stimulate nerve axons during the first month of implant. This 
is the critical time window during which FBR develops and 
electrodes show the most important shift in threshold charge 
and impedance [10], [28]. Other previously proposed 
strategies try to deliver different drugs locally on the implant 
site. However, these strategies have some limitations in the 
case of intraneural electrodes, such as the nerve size, since 
local delivery systems are difficult to adapt to intraneural thin 
electrodes. Our results demonstrate that systemic 
administration of anti-inflammatory drugs may be useful and 
easy to apply. The dosage used in this work, after translation 
to human equivalent dose (HED) [40] is: 
HED = 0.20 mg/kg * 6/37  = 0.032 mg/kg 
which is equal to 2.27 mg/day for a 70 kg adult subject. While 
this dose lies within the range of inflammatory diseases 
treatments [41], possible side-effects should be monitored for 
long-term administration. Since dexamethasone is reducing 
the cellular infiltration during the first month [28], coinciding 
with the improvement in electrode functionality, short-term 
administration can be considered for future experiments. 
Moreover, stronger effects could be expected in more stable 
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models of electrode implantation, such those observed in brain 
implants [25], or in larger nerves (i.e., human implants), since 
the size mismatch between rat nerves and the implanted 
electrodes is more prominent than in larger species. 
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